This article is more than 5 years old. Information may no longer be current.

Glucose variability not a risk factor for neuropathy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

45th Annual Meeting of the European Association for the Study of Diabetes

Glucose variability does not appear to be an additional risk factor for the development of diabetic neuropathy, researchers suggested here.

Using data from the Diabetes Control and Complications Trial (DCCT), researchers in The Netherlands and United Kingdom assessed glycemic variability as a risk factor for the development of peripheral or autonomic diabetic neuropathy. Seven-point glucose profiles were collected four times per year during the DCCT among 1,441 patients with type 1 diabetes. The researchers assessed peripheral neuropathy at baseline and four years follow-up.

Glucose variability had no effect on the incidence of clinical neuropathy confirmed by autonomic or electromyography abnormalities (OR=1.07; 95% CI, 0.83-1.35) or clinical neuropathy alone (OR=0.95; 95% CI, 0.77-1.18).

While glucose variability appeared to have an effect on overall autonomic dysfunction, the effect did not remain when adjusting for HbA1c or mean glucose.

"With respect to the prevention of diabetic neuropathy, we recommend to maintain the focus at achieving overall better glycemic control," Sarah Siegelaar, MD, of the department of internal medicine at Academic Medical Center of the University of Amsterdam, told Endocrine Today. - by Katie Kalvaitis

For more information:

• Vriesendorp TM. OP 30 #179. Presented at: the 45th Annual Meeting of the European Association for the Study of Diabetes; Sept. 29-Oct. 2, 2009; Vienna.